Explore 3 Stock Ideas & Industry Insights Download Free Report

Zymeworks Inc. Common Stock

Company price
26.61 USD 0.57 ( 2.19%)
Last update at 2026-11-19T15:25:00Z
VOLUME
71909
Market Cap
815.99M

Momentum Score

…

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
25.50
Low
26.73
High
52 Week Price Range
8.21
Low
17.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
26.04
Dividend Yield
-
Revenue TTM
93.38M
Revenue Per Share
1.24
Gross Profit TTM
-46.11M
Debt / Equity
0.05
ROE
-29.80%
Net Debt
-47625.00M
ROCE
31.62%
Diluted EPS TTM
-1.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 135.23M -212.36M -180.12M -146.02M -34.38M
Net income 124.34M -211.84M -180.55M -145.44M -36.56M
Selling general administrative 73.36M 42.56M 57.88M 64.18M 29.46M
Gross profit 412.48M 26.68M 38.95M 29.54M 53.02M
Reconciled depreciation 12.00M 12.22M 10.28M 7.33M 3.63M
Ebit 118.52M -225.22M -197.75M -151.30M -36.76M
Ebitda 130.53M -215.63M -187.47M -149.76M -33.13M
Depreciation and amortization 12.00M 9.58M 10.28M 1.54M 3.63M
Non operating income net other - 1.31M 7.34M 5.28M -1.09M
Operating income 130.53M -215.63M -187.47M -151.30M -33.13M
Other operating expenses 281.95M 242.31M 226.42M 180.08M 86.15M
Interest expense 3.60M 12.86M 17.62M 11.08M 0.17M
Tax provision 10.89M -0.52M 0.43M -0.58M 2.17M
Interest income 3.60M 2.51M 5.70M 6.02M 2.64M
Net interest income 3.60M 2.51M 5.70M 6.02M 2.47M
Extraordinary items - - - -0.01M -0.00M
Non recurring - - - 0.77M -
Income tax expense 10.89M -0.52M 0.43M -0.58M 2.17M
Total revenue 412.48M 26.68M 38.95M 29.54M 53.02M
Total operating expenses 281.95M 242.31M 226.42M 180.08M 86.15M
Cost of revenue - - - 115.90M 56.93M
Total other income expense net 4.71M 3.27M 7.34M 5.28M -1.26M
Net income from continuing ops 124.34M -211.84M -180.55M -145.44M -36.56M
Net income applicable to common shares 124.34M -211.84M -180.55M -145.44M -36.56M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 463.09M 580.88M 648.73M 389.13M 538.38M
Intangible assets 4.58M 25.28M 26.38M 21.47M 22.93M
Other current assets 18.86M 19.12M 19.07M 20.00M 13.43M
Total liab 124.32M 116.07M 155.77M 140.04M 128.45M
Total stockholder equity 338768.00M 464.81M 492.96M 249.09M 409.92M
Deferred long term liab - - 17.64M 34.51M 34.12M
Other current liab 49.71M 41.59M 82.09M 7.78M 39.30M
Common stock 1015618.00M 1006.57M 906.76M 741.15M 724.22M
Capital stock 1023.81M 1006.57M 906.76M 741.15M 724.22M
Retained earnings -830335.00M -677.44M -558.76M -683.10M -471.26M
Other liab - - 35.35M 37.26M 36.98M
Good will 12.02M 12.02M 12.02M 12.02M 12.02M
Other assets -162477.36M - 34.71M 34.40M 65.81M
Cash 66103.00M 157.56M 400.91M 201.87M 242.04M
Total current liabilities 88.29M 55.76M 95.62M 71.85M 85.67M
Current deferred revenue 25.59M 3.70M 2.35M 57.59M 37.41M
Net debt -47625.00M -130.84M -372.80M -169.53M -233.39M
Short term debt 2.74M 4.26M 3.32M 1.31M 2.71M
Short long term debt total 18478.00M 26.72M 28.11M 32.33M 8.64M
Other stockholder equity 160437.00M 142.27M 151.61M 197.71M 163.62M
Property plant equipment - - 47.65M 22.78M 12.19M
Total current assets 300.45M 412.93M 544.71M 288.22M 455.08M
Long term investments 98.43M 82.15M 0.89M 0.89M 25.92M
Net tangible assets - - 472.19M 215.61M 374.98M
Short term investments 159.67M 216.77M 91.32M 50.74M 184.32M
Net receivables 55.81M 19.48M 33.40M 15.61M 15.29M
Inventory - 0.00M - - -
Accounts payable 3.90M 6.21M 7.86M 5.17M 6.24M
Accumulated other comprehensive income -6952.00M -6.60M -6.66M -6.66M -6.66M
Common stock total equity - - - 741.15M 724.22M
Retained earnings total equity - - - -683.10M -471.26M
Non currrent assets other 8.92M 7.35M 15.74M 13.70M 3.10M
Non current assets total 162.64M 167.95M 104.02M 100.91M 83.30M
Capital lease obligations 18.51M 26.72M 28.11M 41.23M 8.64M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -53.85M 157.88M -37.17M -11.71M -105.63M
Change to liabilities 26.48M 16.48M 7.62M 21.27M 3.82M
Total cashflows from investing activities -53.85M 144.60M -43.44M -25.59M -109.05M
Net borrowings -0.01M -0.02M -0.04M -0.02M -0.01M
Total cash from financing activities 108.58M 8.01M 308.98M 193.66M 91.43M
Change to operating activities -5.79M -15.82M -4.66M -9.47M -0.25M
Net income 124.34M -211.84M -180.55M -145.44M -36.56M
Change in cash 199.04M -40.17M 113.58M 86.25M 6.26M
Begin period cash flow 201.87M 242.04M 128.45M 42.20M 35.95M
End period cash flow 400.91M 201.87M 242.04M 128.45M 42.20M
Total cash from operating activities 144.11M -192.45M -151.40M -81.85M 24.18M
Issuance of capital stock 107.53M 0.00M 300.91M 188.23M 90.75M
Depreciation 12.00M 9.58M 10.28M 7.33M 3.63M
Other cashflows from investing activities - -0.88M -1.96M -7.56M -2.62M
Dividends paid - - -1.11M -0.60M -
Change to inventory - - - -9.77M -0.11M
Change to account receivables -17.51M -0.27M -13.11M -1.83M -0.12M
Sale purchase of stock 1.40M 2.07M 1.11M 0.60M 91.43M
Other cashflows from financing activities -0.34M 5.96M 8.11M 5.45M 0.69M
Change to netincome 3.75M 9.20M 28.93M 49.54M 16.94M
Capital expenditures 13.12M 13.29M 6.26M 13.88M 3.42M
Change receivables - -0.27M -13.11M -1.83M -0.12M
Cash flows other operating - -12.55M -1.81M -10.83M 36.46M
Cash and cash equivalents changes - -39.84M 114.14M 86.22M 6.56M
Change in working capital 4.01M 0.39M -10.15M 6.44M 39.92M
Stock based compensation 4.01M 10.76M 29.12M 49.00M 13.44M
Other non cash items -2.21M -0.39M -0.36M 1.54M 3.75M
Free cash flow 130.98M -205.74M -157.67M -95.73M 20.76M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZYME
Zymeworks Inc. Common Stock
0.57
2.19%
26.61 - - 8.74 2.51 6.09 0.34
NVO
Novo Nordisk A/S
-0.34
0.86%
39.09 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.95
1.30%
529.50 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-18.50
1.96%
927.03 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Zymeworks Inc. Common Stock

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

108 Patriot Drive, Middletown, DE, United States, 19709

302 274 8744

299

Name Title Year Born
Mr. Neil A. Klompas C.A., CPA, CA, CPA Pres & COO 1972
Dr. Ali Tehrani Ph.D. Advisor 1972
Dr. Neil Josephson M.D. Chief Medical Officer 1961
Mr. Kenneth H. Galbraith C.A. CEO & Chairman 1963
Dr. Christopher Astle Ph.D. Sr. VP & CFO 1980
Dr. Paul Moore Ph.D. Chief Scientific Officer NA
Jack W. Spinks Mang. of Investor Relations NA
Mr. Daniel Dex J.D., Ph.D. VP of Legal & Corp. Sec. NA
Mr. Mark Hollywood Sr. VP of Technical & Manufacturing Operations 1970
Dr. David Poon Ph.D. VP of Bus. Devel. and Alliance Management NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…